Dataset Information

Beyond Traditional SPAAC: Achieving Orthogonality and Rapid Kinetics with Fluoroalkyl Azides

ABSTRACT: Selective modification of biological systems via click reactions is an important method to study their properties and function under native conditions. One of the most used method is the strain-promoted azide-alkyne cycloaddition (SPAAC) reaction between azides and strained cyclooctynes. In this work, we show, that fluorination of the azide reagents enhances their click reactivity and enables achieving of excellent selectivity when used in combination with simple alkyl azides. This work extends the available toolkit for efficient and selective modification of (bio)molecules under benign, metal-free condition.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Frantisek Filandr

LAB HEAD: Milan Vrábel

PROVIDER: PXD066546 | Pride | 2026-05-25

REPOSITORIES: pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	2025-04-23-DAR-Analysis-Pipeline.csv	Csv
	2025-04-23-DAR-Analysis-Pipeline_report.html	Other
	2025-05-02-DAR-Analysis-Pipeline.csv	Csv
	2025-05-02-DAR-Analysis-Pipeline_report.html	Other
	25-04-15-DAR_conf.dat	Other

Items per page:

1 - 5 of 11

Publications

Beyond traditional strain-promoted azide-alkyne cycloadditions by achieving orthogonality and rapid kinetics with fluoroalkyl azides.

Tomčo Matúš M Šlachtová Veronika V Vrábel Milan M Li Jialu J Filgas Josef J Slavíček Petr P Bednárová Lucie L Filandr František F Beier Petr P

Communications chemistry 20260313 1

Strain-promoted azide-alkyne cycloaddition (SPAAC) is a cornerstone of bioorthogonal chemistry, offering metal-free and biocompatible ligation for applications ranging from bioconjugation to live-cell imaging. However, its relatively slow kinetics and limited selectivity hinder the simultaneous labelling of multiple targets. Here, we report on a systematic study of fluoroalkyl azides as SPAAC reagents that display enhanced reactivity with electron-rich cyclooctynes, while showing significantly r ...[more]

PMID: 41839985

Similar Datasets

Project description:HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show antitumor activity in a limited proportion of patients, indicating that HER2 can be still exploited as a target after trastuzumab failure. However, due to the high proportion of patients that fail to respond to these alternative strategies, it is reasonable to assume that cells escaping HER2 targeting may rely on alternative pathways not involving HER2 to sustain their growth. Their knowledge is relevant for exploiting new therapies. To investigate this hypothesis we generated a human HER2 overexpressing breast cancer cell line resistant to trastuzumab and lapatinib (T100) and we have characterized it genetically and molecularly. In T100 cells, the previously proposed mechanisms of resistance to HER2 inhibitors did not explain cell escape. Notably, silencing HER2 by shRNA did not affect the growth of T100 cells, suggesting loss of reliance upon HER2. Among the alternative pathways that we explored, altered levels of the antiapoptoptic proteins Mcl-1 and Survivin were observed. This suggested the possibility of targeting resistant cells with the multitarget inhibitor sorafenib. Moreover, sorafenib, nearly inactive in parental cells, strongly inhibited the in vitro growth of T100 cells. In conclusion, we provide a new model where the activation of HER2 independent mechanisms sustains the growth of tumor cells, significantly increasing the sensitivity to sorafenib. Keywords: HER2, breast cancer, resistance, trastuzumab, lapatinib, sorafenib Total RNA was isolated using TRIZOL reagent (Life Technologies, Gathersburg, MD) and quantified by Bioanalyzer 2100 (Agilent Technologies); following the isolation procedure, mRNA was amplified starting from 1μg using MessageAmp II aRNA Amplification kit (Ambion Inc. Austin TX, USA). Ammino-allyl modified nucleotides were incorporated in in vitro transcription step according to the manufacturer’s protocol. Labeling was performed using NHS (N-hydroxysuccinimidyl) ester Cy3 or Cy5 dies (GE Healthcare Europe GMBH, Upsala - Sweden) able to react with the modified RNA. At least 5 μg of mRNA, for each sample, were labeled and purified with columns respectively. The Dye-Swap replication procedure was applied, in order to increase the accuracy of results. Samples were hybridized on 44K glass arrays (Agilent Technologies). Arrays were scanned and the images obtained were analyzed by the Feature Extraction software Agilent (version 9.5) and the text files were then processed using the Bioconductor package Limma (Linear models for microarray analysis).